3-({1-[3-carbamimidoyl-1-(4-carbamimidoyl-benzylcarbamoyl)-propylcarbamoyl]-2-methyl-butylsulfamoyl}-methyl)-benzoic acid

This compound is a synthetic small molecule with the molecular formula C27H37N7O6S and a molecular weight of approximately 587.7 g/mol. It is listed in chemical and pharmaceutical databases as an experimental agent but does not have an established clinical use or approved indication. The structure contains multiple amidine (guanidino), carbamoyle, sulfonamide, and benzoic acid moieties. There is no evidence of clinical trials or regulatory approval for any disease area as of June 2025[2][3]. Based on related patent literature describing similar structures, compounds in this class are designed as protease inhibitors—specifically targeting serine proteases involved in coagulation pathways such as thrombin or factor Xa—suggesting potential antithrombotic activity[5]. However, there are no direct data confirming its mechanism of action or therapeutic application for this specific molecule.

Other names

3-({[(1R,2R)-1-{[(1S)-3-carbamimidoyl-1-{[(4-carbamimidoylphenyl)methyl]carbamoyl}propyl]carbamoyl}-2-methylbutyl]sulfamoyl}methyl)benzoic acid3-((((1R,2R)-1-(((1S)-3-carbamimidoyl-1-(((4-carbamimidoylphenyl)methyl)carbamoyl)propyl)carbamoyl)-2-methylbutyl)sulfamoyl)methyl)benzoic acidN-[(3-carboxybenzyl)sulfonyl]isoleucyl-N~1~-{4-[amino(imino)methyl]benzyl}-5-iminoornithinamide[1][2]